, a global leader in innovation, today announced the commencement of a clinical trial in Europe for RAPROS®, an oral medication for chronic kidney disease in cats.Feline CKD is a progressive condition that weakens
, causing symptoms like loss of appetite and weight. Without proper management, the risk of death rises considerably. Existing treatments have proven inadequate for many years.In 2017, Toray achieved a breakthrough in Japan, receiving approval to manufacture and market RAPROS® for feline CKD. Kyoritsu Seiyaku Corporation distributes the medication, which became the first veterinary drug to demonstrably slow the decline of kidney function.
Toray aims to make veterinary medicine better by developing new treatments that help pets and their owners around the world.